Table 2.
Programme impact and cost assumptions used for RSV prevention strategies in the model comparison exercise
| Input parameter | Maternal vaccine | Source | Infant mAb | Source |
|---|---|---|---|---|
| Impact of RSV prevention strategy | ||||
| Programme coverage* | ANC (proxy) | Baral et al. [16] | BCG (proxy) | WUENIC [50] |
| Efficacy (RSV severe cases) | 69.4% | Pfizer [34] | 77.3% | Sanofi [52] |
| Efficacy (RSV non-severe cases) | 51.3% | Pfizer [34] | 74.5% | Sanofi [52] |
| Duration of protection (fixed for n months) | 6 | Pfizer [34] | 5 | Sanofi [52] |
| Percentage wastage | ||||
| Doses | 5.00% | Assumption | 5.00% | Assumption |
| Syringes | 5.00% | Assumption | 5.00% | Assumption |
| Safety boxes | 5.00% | Assumption | 5.00% | Assumption |
| Price per dose (US$) | ||||
| GAVI countries | US$ 3.50 | Assumption | US$ 3.50 | Assumption |
| Non-GAVI countries | US$ 7.00 | Assumption | US$ 7.00 | Assumption |
| International handling (% of dose price) | ||||
| GAVI countries | 1.40% | UNICEF [58] | 1.40% | UNICEF [58] |
| Non-GAVI countries | 3.50% | UNICEF [58] | 3.50% | UNICEF [58] |
| International transportation (% of dose price) | ||||
| All countries | 6.00% | Debellut [61] | 6.00% | Debellut [61] |
| Other injection supply costs | ||||
| Syringe price per dose (US$) | US$ 0.0278 | UNICEF [54] | US$ 0.0278 | UNICEF [54] |
| Safety box price per dose (US$) | US$ 0.0121 | UNICEF [54] | US$ 0.0121 | UNICEF [54] |
| Incremental health system cost per dose (US$) | ||||
| Low-income countries | US$ 0.74 | ICAN [62] | US$ 0.74 | ICAN [62] |
| Middle-income countries | US$ 2.02 | ICAN [62] | US$ 2.02 | ICAN [62] |